吉非替尼治疗23例晚期非小细胞肺癌

背景与目的:有临床研究表明分子靶向药物吉非替尼单药治疗NSCLC有效,本文旨在研究吉非替尼治疗晚期非小细胞肺癌的疗效及其安全性。方法:23例晚期非小细胞肺患者每日均口服吉非替尼250mg,直至患者不能耐受或病情进展时停药,观察患者症状、近期疗效、肿瘤无进展时间、生存期及不良反应。结果:23例患者至少服药1个月,其中用药后咳嗽、胸痛等症状缓解的有13例,无缓解的有3例,病情持续加重的有7例。影像学显示,肺、脑等转移灶减小的有11例(47.8%),无变化或增大的各6例(各占26.1%)。CR2例(8.7%),PR10例(43.5%),SD4例(17.4%),PD7例(30.4%)。有效率(RR)为52.2%,疾病控制率(DCR)为69.6%。患者肿瘤无进展中位时间5个月(0～15个月),至随访结束时,8例死亡,15例生存。副作用有皮疹10例(43.5%),4例(17.4%)消化道反应表现为溃疡与腹泻症状。结论:用吉非替尼治疗晚期非小细胞肺癌效果较好且安全。

Gefinitib in treatment of 23 patients with advanced non-small cell lung cancer

Background and purpose:It is reported that gefitinib is effective in non-small cell lung cancer(NSCLC).This paper aimed to explore the effects and safety of gefitinib treatment in advanced stage of non-small lung cancer.Methods:23 patients were treated with 250 mg gifitinib every day until either disease progressed or severe side effects occurred,the clinical symptoms,immediate treatment response,median survival time,adverse effects were observed.Results:Symptoms of cough and chest ache alleviated in 13 patients one month after treatment,3 patients were not alleviated and 7 of 13 patients had worse complains.The size of tumor was smaller than before treatment in 11 patients,and no changes or increase of tumor size was documented in other patients.Among the 23 patients,2 cases(8.7%)got CR,10 cases(43.5%)with PR,4 cases(17.4%)with SD,7 case(30.4%)with PD,RR 52.2%,DCR 69.6%,median survival time without tumor were 5 months(0-15 months).Main adverse effects were skin rash and diarrhea in alimentary tract.Conclusions:The treatment with gefitinib in patients with advanced non-small lung cancer is effective and safe.